INCYTE CORP (INCY) Stock Analysis — April 2026 Rating, Price, and Forecast
Company Overview — What Does INCYTE CORP Do?
Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States and internationally. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in various liquid and solid tumor types; and ICLUSIG, a kinase inhibitor to treat chronic myeloid leukemia and philadelphia-chromosome positive acute lymphoblastic leukemia. Its clinical stage products include ruxolitinib, a steroid-refractory chronic graft-versus-host-diseases (GVHD); itacitinib, which is in Phase II/III clinical trial to treat naïve chronic GVHD; and pemigatinib for treating bladder cancer, cholangiocarcinoma, myeloproliferative syndrome, and tumor agnostic. In addition, the company engages in developing Parsaclisib, which is in Phase II clinical trial for follicular lymphoma, marginal zone lymphoma, and mantel cell lymphoma. Additionally, it develops Retifanlimab that is in Phase II clinical trials for MSI-high endometrial cancer, merkel cell carcinoma, and anal cancer, as well as in Phase II clinical trials for patients with non-small cell lung cancer. It has collaboration agreements with Novartis International Pharmaceutical Ltd.; Eli Lilly and Company; Agenus Inc.; Calithera Biosciences, Inc; MacroGenics, Inc.; Merus N.V.; Syros Pharmaceuticals, Inc.; Innovent Biologics, Inc.; Zai Lab Limited; Cellenkos, Inc.; and Nimble Therapeutics, as well as clinical collaborations with MorphoSys AG and Xencor, Inc. to investigate the combination of tafasitamab, plamotamab, and lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma, and relapsed or refractory follicular lymphoma. The company was incorporated in 1991 and is headquartered in Wilmington, Delaware. INCYTE CORP (INCY) is classified as a large-cap stock in the Industrials sector, specifically within the Business Services industry. The company is led by CEO Herve Hoppenot and employs approximately 2,320 people, headquartered in Wilmington, Delaware. With a market capitalization of $18.8B, INCY is one of the prominent companies in the Industrials sector.
INCYTE CORP (INCY) Stock Rating — Hold (April 2026)
As of April 2026, INCYTE CORP receives a Hold rating with a composite score of 47.8/100 and 3 out of 5 stars from the Blank Capital Research quantitative model.INCY ranks #1,159 out of 4,446 stocks in our coverage universe. Within the Industrials sector, INCYTE CORP ranks #185 of 752 stocks, placing it in the top quartile of its Industrials peers. The rating is generated by a multi-factor model that weighs quality (30%), momentum (25%), value (15%), investment (10%), stability (10%), and short interest (10%).
INCY Stock Price and 52-Week Range
INCYTE CORP (INCY) currently trades at $96.49. The stock lost $0.47 (0.5%) in the most recent trading session. The 52-week high for INCY is $112.29, which means the stock is currently trading -14.1% from its annual peak. The 52-week low is $53.56, putting the stock 80.2% above its annual trough. Recent trading volume was 1.1M shares, reflecting moderate market activity.
Is INCY Overvalued or Undervalued? — Valuation Analysis
INCYTE CORP (INCY) carries a value factor score of 49/100 in the Blank Capital model, indicating fair valuation relative to historical norms. The trailing price-to-earnings ratio is 17.05x, compared to the Industrials sector average of 28.33x — a discount of 40%. The price-to-book ratio stands at 4.01x, versus the sector average of 2.23x. The price-to-sales ratio is 3.91x, compared to 0.50x for the average Industrials stock. On an enterprise value basis, INCY trades at 14.07x EV/EBITDA, versus 5.70x for the sector.
Overall, INCY's valuation appears roughly in line with sector benchmarks, suggesting the market is pricing the stock fairly given its current fundamentals and growth trajectory. Neither deep value nor significantly overpriced, the stock occupies a middle ground on valuation.
INCYTE CORP Profitability — ROE, Margins, and Quality Score
INCYTE CORP (INCY) earns a quality factor score of 50/100, indicating solid business quality with consistent operational execution. The return on equity (ROE) is 23.5%, compared to the Industrials sector average of 8.9%, which demonstrates strong shareholder value creation. Return on assets (ROA) comes in at 17.3% versus the sector average of 3.3%.
On a margin basis, INCYTE CORP reports gross margins of 92.9%, compared to 35.8% for the sector. The operating margin is 27.1% (sector: 6.2%). Net profit margin stands at 22.2%, versus 3.9% for the average Industrials stock. Revenue growth is running at 30.9% on a trailing basis, compared to 6.4% for the sector. The overall profitability profile is adequate, though there may be room for margin expansion.
INCY Debt, Balance Sheet, and Financial Health
INCYTE CORP has a debt-to-equity ratio of 36.0%, compared to the Industrials sector average of 70.0%. The low leverage indicates a conservative balance sheet with significant financial flexibility. The current ratio is 3.20x, indicating strong short-term liquidity. Cash and equivalents stand at $2.46B.
INCY has a beta of 0.60, meaning it is less volatile than the S&P 500, making it a relatively defensive holding. The stability factor score for INCYTE CORP is 76/100, indicating low-volatility characteristics and consistent price behavior that appeals to risk-averse investors.
INCYTE CORP Revenue and Earnings History — Quarterly Trend
In TTM 2026, INCYTE CORP reported revenue of $4.77B and earnings per share (EPS) of $2.17. Net income for the quarter was $1.09B. Gross margin was 92.9%. Operating income came in at $1.33B.
In Q3 2025, INCYTE CORP reported revenue of $1.37B and earnings per share (EPS) of $2.17. Net income for the quarter was $424M. Gross margin was 92.8%. Revenue grew 20.0% year-over-year compared to Q3 2024. Operating income came in at $444M.
In Q2 2025, INCYTE CORP reported revenue of $1.22B and earnings per share (EPS) of $2.09. Net income for the quarter was $405M. Gross margin was 93.5%. Revenue grew 16.5% year-over-year compared to Q2 2024. Operating income came in at $530M.
In Q1 2025, INCYTE CORP reported revenue of $1.05B and earnings per share (EPS) of $0.82. Net income for the quarter was $158M. Gross margin was 93.0%. Revenue grew 19.5% year-over-year compared to Q1 2024. Operating income came in at $205M.
Over the past 8 quarters, INCYTE CORP has demonstrated a growth trajectory, with revenue expanding from $881M to $4.77B. Investors analyzing INCY stock should weigh these quarterly trends alongside the valuation and quality metrics discussed above.
INCY Dividend Yield and Income Analysis
INCYTE CORP (INCY) does not currently pay a dividend. This is common among growth-oriented companies in the Business Services industry that prefer to reinvest cash flows into business expansion rather than returning capital to shareholders. Income-focused investors looking for Industrials dividend stocks may want to explore other Industrials stocks or use the stock screener to filter by dividend yield.
INCY Momentum and Technical Analysis Profile
INCYTE CORP (INCY) has a momentum factor score of 59/100, reflecting neutral trend characteristics. The stock is neither significantly outperforming nor underperforming the broader market on a momentum basis. The investment factor score is 24/100, which measures capital allocation efficiency and asset growth patterns. The short interest score of 6/100 signals elevated short interest, which can indicate bearish sentiment among institutional investors.
INCY vs Competitors — Industrials Sector Ranking and Peer Comparison
Within the Industrials sector, INCYTE CORP (INCY) ranks #185 out of 752 stocks based on the Blank Capital composite score. This places INCY in the top quartile of all Industrials stocks in our coverage universe. Key competitors and sector peers include South Bow Corp (SOBO) with a score of 56.5/100, TSAKOS ENERGY NAVIGATION LTD (TEN) with a score of 61.4/100, Great Lakes Dredge & Dock CORP (GLDD) with a score of 56.7/100, Tri Pointe Homes, Inc. (TPH) with a score of 57.3/100, and Clear Channel Outdoor Holdings, Inc. (CCO) with a score of 52.2/100.
Comparing INCY against the S&P 500 benchmark is also instructive for understanding relative performance. Investors can view the full INCY vs S&P 500 (SPY) comparison to assess how INCYTE CORP stacks up against the broader market across all factor dimensions.
INCY Next Earnings Date
No upcoming earnings date has been announced for INCYTE CORP (INCY) at this time. Check the earnings calendar for the latest scheduling updates across all stocks in our coverage universe.
Should You Buy INCY? — Investment Thesis Summary
INCYTE CORP presents a balanced picture with arguments on both sides. Low volatility (stability score 76/100) reduces downside risk.
In summary, INCYTE CORP (INCY) earns a Hold rating with a composite score of 47.8/100 as of April 2026. The rating is derived from the Blank Capital Research methodology, which combines six factor dimensions into a single quantitative ranking. Investors should consider these quantitative signals alongside their own fundamental research, risk tolerance, and investment time horizon before making buy or sell decisions on INCY stock.
Related Resources for INCY Investors
Explore more research and tools: INCY vs S&P 500 comparison, top Industrials stocks, stock screener, our methodology, quality factor explained, value factor explained, momentum factor explained. Compare INCY head-to-head with peers: INCY vs SOBO, INCY vs TEN, INCY vs GLDD.